Work

AML-108 SELECT-AML-1 Trial in Progress: A Phase 2 Study of Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-Positive AML who are Ineligible for Standard Induction Therapy

Year: 2022

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(22)01221-6

Authors: Suman Kambhampati, Alireza Eghtedar, Christine McMahon, Stephane de Botton, Arnaud Pigneux, Brian Ball, Gautam Borthakur, Angela Volkert, Joanie Aasen Gausman, Kristen Baker, Graeme Hodgson, Erica Warlick, David Roth, Michael Kelly, Daniel Pollyea, Eytan Stein

Institutions: Colorado Blood Cancer Institute, Institut Gustave Roussy, Centre Hospitalier Universitaire de Bordeaux, City Of Hope National Medical Center, City of Hope, The University of Texas MD Anderson Cancer Center, Syros Pharmaceuticals (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4296468343

Cites:

Cited by:

Related to: 10